Vanguard Group Inc. Purchases 2,545,381 Shares of Boston Scientific Corporation $BSX

Vanguard Group Inc. boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 137,134,110 shares of the medical equipment provider’s stock after buying an additional 2,545,381 shares during the period. Vanguard Group Inc. owned about 0.09% of Boston Scientific worth $14,729,575,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in BSX. Bessemer Group Inc. increased its stake in shares of Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. Swedbank AB increased its position in Boston Scientific by 114.5% during the 2nd quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after purchasing an additional 1,505,019 shares during the period. Goldman Sachs Group Inc. increased its position in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. Finally, Ninety One UK Ltd raised its holdings in shares of Boston Scientific by 33.5% in the 2nd quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock valued at $552,755,000 after purchasing an additional 1,290,414 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 175,782 shares of company stock worth $17,742,314. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 1.0%

Shares of Boston Scientific stock opened at $101.71 on Tuesday. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The business’s fifty day moving average is $99.59 and its two-hundred day moving average is $102.55. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $150.78 billion, a PE ratio of 54.39, a P/E/G ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the firm posted $0.63 EPS. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BSX. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Wells Fargo & Company raised their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. UBS Group lifted their target price on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Finally, Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.